| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | December 20, 2024 4:30 P.M. |
| Form: | S-1 | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/29/2024 | $17.00 | Buy | ROTH MKM |
MINNEAPOLIS, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that Nestor Jaramillo, Jr. retired as President and Chief Executive Officer and as a director of the company, effective February 18, 2025. John Erb, who currently serves as Chairman of the company's Board of Directors, assumed the role of Interim President and Chief Executive Officer and assumed all of the duties formerly performed by Mr. Jaramillo. Nuwellis intends to retain an executive search firm to assist in identifying a permanent CEO. Mr. Erb, stated, "Nestor has been with the company for nearly si
MINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the appointment of Dave McDonald and Archelle Georgiou, MD, to its board of directors, effective November 1, 2023. "With decades of experience and leadership in their respective fields, we welcome Dave and Archelle to our board. Dave's significant experience in finance and strategy will provide key insights to our board as we advance our growth and expansion initiatives. In turn, our board will benefit from perspectives gained from Archelle's healthcare policy, clinical, and patient education experience
MINNEAPOLIS, June 05, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of patients suffering from fluid overload, today announced that Mike McCormick has been appointed to the company's Board of Directors. Mr. McCormick's vast experience includes more than 25 years of service in the medical device industry through varying leadership roles for several private and publicly traded companies. Mr. McCormick will also serve as Lead Independent Director and serve as a member of the Audit Committee and as Chair of the Nominating and Corporate Governance Committee of the Board. "We are delighted to welcome Mike to Nuwellis' Board
10-Q - Nuwellis, Inc. (0001506492) (Filer)
8-K - Nuwellis, Inc. (0001506492) (Filer)
8-K - Nuwellis, Inc. (0001506492) (Filer)
SC 13G - Nuwellis, Inc. (0001506492) (Subject)
SC 13G - Nuwellis, Inc. (0001506492) (Subject)
SC 13G - Nuwellis, Inc. (0001506492) (Subject)
MINNEAPOLIS, May 13, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a commercial-stage medical device company dedicated to transforming care for fluid overload patients, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. First Quarter 2025 and Recent Business Highlights Nuwellis continued to advance its strategic priorities during the first quarter, delivering growth in customer categories and strengthening the foundation for broader adoption of Aquadex therapy. Higher CMS reimbursement, strong pediatric performance, and disciplined expense management position the company to capitalize on both inpatient growth and em
MINNEAPOLIS, April 22, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a commercial-stage medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the first quarter 2025 on May 13, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-579-2543 (U.S) or 1-785-424-1789 (international) and using the conference ID: NUWEQ1. An a
MINNEAPOLIS, March 11, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a commercial-stage medical device company focused on transforming the lives of people with fluid overload, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights: CMS four-fold payment increase to $1,639 for Aquadex Ultrafiltration Therapy in the outpatient setting effective January 1, 2025.New data published in JACC: Heart Failure showed Aquadex ultrafiltration reduced heart failure events by 60% compared to IV diuretics.Full year operating cost reduction of $5.9 million, or 26%, compared to the pr
4 - Nuwellis, Inc. (0001506492) (Issuer)
4 - Nuwellis, Inc. (0001506492) (Issuer)
4 - Nuwellis, Inc. (0001506492) (Issuer)
MINNEAPOLIS, May 13, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a commercial-stage medical device company dedicated to transforming care for fluid overload patients, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. First Quarter 2025 and Recent Business Highlights Nuwellis continued to advance its strategic priorities during the first quarter, delivering growth in customer categories and strengthening the foundation for broader adoption of Aquadex therapy. Higher CMS reimbursement, strong pediatric performance, and disciplined expense management position the company to capitalize on both inpatient growth and em
Strategic agreement is expected to reduce costs, preserve expertise, and streamline operations. WHOWHATWHEREWHENWHYNuwellis, Inc. (NASDAQ:NUWE) and KDI Precision ManufacturingOutsourcing manufacturing and assembly of key Aquadex product components.Manufacturing operations will transition to KDI's facility.May 9, 2025To strengthen operational efficiency, preserve product expertise, and reduce costs. MINNEAPOLIS, May 12, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company dedicated to transforming fluid management care, today announced it has finalized an agreement with KDI Precision Manufacturing to support the next phase of Nuwellis' growth. This strateg
MINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on fluid management solutions for patients with fluid overload, today announced a meaningful step forward for children facing fluid overload with the recent expansion of its Aquadex SmartFlow® therapy into two additional pediatric centers across the Southeastern United States. The company now has 47 pediatric centers that have adopted Aquadex therapy as part of their fluid management approach. Even in well-managed care settings, fluid overload can be a turning point in recovery for pediatric patients—who often have a narrow margin for error. When alternative therapies fall
ROTH MKM initiated coverage of Nuwellis with a rating of Buy and set a new price target of $17.00